Drug-labels.com

Novo-Ursodiol: Uses, Side Effects and Dosage

Updated:
Facts
Status:
Prescription (Rx) Current status: Cancelled Pre Market
Strength:
250 mg, 500 mg
Active ingredient:
Similar drugs:

Patient Medication Information: uses, side effects, how to take - Novo-Ursodiol

ABOUT THIS MEDICATION

What the medication is used for:

NOVO-URSODIOL has been prescribed for you by your physician for the management of cholestatic liver disease. NOVO-URSODIOL are only available by prescription.

What it does:

NOVO-URSODIOL contain ursodiol (ER-so-DYE-all), which is a naturally occurring bile acid found in small quantities in normal human bile.

In patients with cholestatic liver disease the release and flow of bile through the bile ducts are reduced. By taking NOVO-URSODIOL the amount of ursodiol in the bile increases, changing the make-up of the bile and causing an increase in bile flow. Ursodiol also works by replacing toxic bile acids that can destroy liver tissue.

When it should not be used:

If you are allergic (hypersensitive) to NOVO-URSODIOL, or any of the nonmedicinal ingredients (see list below).

What the medicinal ingredient is:

ursodiol (USP)

What the nonmedicinal ingredients are:

NOVO-URSODIOL contains the following excipients: colloidal silicon dioxide, magnesium stearate, microcrystalline cellulose, polyethylene glycol, povidone, sodium lauryl sulphate, sodium starch glycolate, hypromellose, Ethylcellulose, cetyl alcohol, dibutyl sebacate.

What dosage forms it comes in:

250 mg tablet

Novo-Ursodiol is available in strength of 250 mg as white to off-white, oval shaped, film coated tablet, debossed with “93” on one side of the tablet and with “5360” on the other side of the tablet. They are supplied in HDPE bottles containing 100 and 500 tablets and in unit dose of 100 tablets.

500 mg tablet

Novo-Ursodiol is available in strength of 500 mg as white to off-white, oval shaped, film coated tablet, debossed with “93” on one side of the tablet and with “5361” on the other side of the tablet. They are supplied in HDPE bottles containing 100 and 500 tablets and in unit dose of 100 tablets.

WARNINGS AND PRECAUTIONS

Before you take NOVO-URSODIOL, tell your doctor if:

  • You have taken ursodiol before and it was not well-tolerated or caused an allergy.
  • You have liver problems, or are in need of a liver transplant.
  • You have variceal bleeding (bleeding from swollen veins, arteries, or lymph vessels).
  • You have ascites (swelling in the abdomen).
  • You are taking other prescription or non-prescription medicines.
  • You are using any new medicine

    (prescription or non-prescription) such as bile reduction medicines (cholestyramine or colestipol), aluminum based antacids (Rolaids, Maalox, Mylanta, and many others), and cyclosporine, nitrendipine, or dapsone.

  • You develop any new medical problem while using this medicine.
  • You have severe stomach pain.
  • You are pregnant, plan to become pregnant,

    are breast-feeding or plan to breast-feed.

  • You need other medical treatment by

    another doctor, let him or her know that you are taking ursodiol.

NOVO-URSODIOL is not recommended for use in children.

You should discuss with your doctor the benefits and risks of taking NOVO-URSODIOL for your medical condition.

This medication is prescribed for a particular health problem and for your personal use only. Do not give it to another person.

Keep this and all other medicines out of the reach of children.

INTERACTION WITH THIS MEDICATION

The following medicines may decrease the amount of ursodiol that is absorbed into your body:

  • Medicines that reduce the amount of bile

    acids such as cholestyramine or colestipol

  • Antacids that contain aluminum such as

    Rolaids, Maalox, Mylanta, and many others.

The absorption and metabolism of the following medicines may be affected by taking ursodiol:

  • Cyclosporine
  • Dapsone
  • Nitrendipine

Use of these medicines with NOVO-URSODIOL may require patients to be closely monitored and the dose of their medicines adjusted.

PROPER USE OF THIS MEDICATION

Usual Adult Dose:

Your doctor would have prescribed the amount of NOVO-URSODIOL you should take each day for your medical condition. NOVO-URSODIOL should be taken in 2 to 4 divided doses with food. It is easier to remember to take your medication, if it is taken at the same time each day. Setting up a routine to take your medication helps this activity become a normal part of your day.

Take NOVO-URSODIOL for the full duration of treatment, even if you begin to feel better.

This medication should only be used as instructed by your doctor. Follow your doctor’s instructions. Do not change the dose or stop the treatment without your doctor’s advice.

Your doctor will ask you to have regular medical checkups, and will likely require liver tests. It is important to respect the dates proposed.

Overdose:

The most severe symptom of overdosage would likely be diarrhea.

In case of drug overdose, contact a health care practitioner, hospital emergency department or regional Poison Control Centre immediately, even if there are no symptoms.

Missed Dose:

If you miss a dose, take the missed dose as soon as you remember. If it is almost time for your next dose, skip the dose you missed and take your next regularly scheduled dose. Do not take a double dose.

SIDE EFFECTS AND WHAT TO DO ABOUT THEM

Side effects while taking ursodiol may include diarrhea, nausea, indigestion, heartburn, stomach ulcers, chest pain, high blood pressure, low blood platelet count, swelling, loss of energy, skin rash, and itching.

If you have severe stomach pain, contact your doctor.

This is not a complete list of side effects. For any unexpected effects while taking NOVO-URSODIOL contact your doctor or pharmacist.

HOW TO STORE IT

NOVO-URSODIOL tablets should be stored at room temperature (15°-30° C) in a closed container.

Keep this and all other medication out of the reach of children.

MORE INFORMATION

This document plus the full product monograph, prepared for health professionals can be found by contacting Teva Canada Limited at:

1-800-268-4127 ext. 5005 (English);

1-877-777-9117 (French)

or druginfo@tevacanada.com

Novopharm Limited

30 Novopharm Court

Toronto, Ontario

Canada, M1B 2K9

Last revised: June 23, 2011

REPORTING SUSPECTED SIDE EFFECTS

You can report any suspected adverse reactions associated with the use of health products to the Canada Vigilance Program by one of the following 3 ways:

-------------------------------------------------------------

  • Report online at

    www.healthcanada.gc.ca/medeffect

  • Call toll-free at 1-866-234-2345
  • Complete a Canada Vigilance Reporting

    Form and:

    • Fax toll-free to 1-866-678-6789, or
    • Mail to:

      Canada Vigilance Program Health Canada

      Postal Locator 0701D Ottawa, ON K1A 0K9

Postage paid labels, Canada Vigilance Reporting Form and the adverse reaction reporting guidelines are available on the MedEffect™ Canada Web site at www.healthcanada.gc.ca/medeffect.

NOTE: Should you require information related to the management of side effects, contact your health professional. The Canada Vigilance Program does not provide medical advice.

About this document

Source: Health Canada – Drug Product Database (DPD) and product monographs · DIN (Drug Identification Number): 02318091

Revision date stated in the text: June 23, 2011

Found a mistake? Write to us via the contact page.

The information on this site does not replace the advice of a doctor or pharmacist.

Drug information for Novo-Ursodiol

Rx or OTC
Prescription (Rx)?
DIN 02318091, 02318105
Schedule(s) PRESCRIPTION
Active ingredient(s) Ursodiol
Dosage form(s) Tablet
Route(s) of administration Oral
Drug class (WHO ATC)
  1. A Alimentary tract and metabolism drugs
    1. A05 Bile and liver therapy drugs
      1. A05A Bile therapy drugs
        1. A05AA Bile acids and derivatives for bile therapy
          1. A05AA02 Ursodeoxycholic acid
Company NOVOPHARM LIMITED
Current status Cancelled Pre Market
Current status date July 24, 2018
Strengths and forms
DIN Strength Dosage form(s) Current status
02318091 250 MG Tablet Cancelled Pre Market July 24, 2018
02318105 500 MG Tablet Cancelled Pre Market July 24, 2018

Source: Health Canada – Drug Product Database (DPD) and product monographs, data as of November 1, 2026. Data from the Health Canada Drug Product Database, as published there. Not a substitute for the advice of a doctor or pharmacist.